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Abstract

Signaling Pathways Coupled to Melatonin Receptor MT1a in
Gastric Smooth Muscle
By
Rashad Ahmed, B.S.
A thesis submitted in partial fulfillment of the requirements for the degree of
Masters of Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2009.
Director: S. Murthy Karnam, Ph.D.
Professor, Department of Physiology and Biophysics

The Melatonin, a close derivative of serotonin, is involved in physiological regulation of
circadian rhythms.

In the gastrointestinal (GI) system, melatonin exhibits endocrine,

paracrine and autocrine actions and is implicated in the regulation of GI motility.
Generally, melatonin actions oppose the stimulatory actions of serotonin on motility.
However, it is not known whether melatonin can also act directly on GI smooth muscle
cells. The aim of the present study was to determine the expression of melatonin receptors
in smooth muscle and identify their signaling pathways. Muscle cells were isolated from
rabbit distal stomach by enzymatic digestion, filtration and centrifugation and cultured in
DMEM-10. Expression of melatonin receptors, MT1 and MT2, was determined by RTPCR and Western blot. G protein activity was measured by melatonin-induced increase in
Gα binding to [35S]GTPγS.

Phosphoinositide (PI)-specific phospholipase C (PLC-β)

activity was measured by ion-exchange chromatography. Cytosolic Ca2+ was measured in
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fura-2 loaded cells and muscle contraction was measured by scanning micrometry. In
cultured gastric smooth muscle cells MT1 was detected by RT-PCR and western blot.
Melatonin activated Gαq, but not Gαs, Gαi1, Gαi2, or Gαi3. Consistent with activation of
Gαq, melatonin stimulated PLC-β activity (PI hydrolysis), increased cytosolic Ca2+, and
elicited muscle contraction. Stimulation of PLC-β activity was blocked by the expression
of Gαq minigene and contraction was blocked by the PLC-β inhibitor, U73122. We
conclude that gastric smooth muscle cells express receptors for melatonin (MT1) coupled
to Gq. The receptors mediate stimulation of PLC-β activity and increase in cytosolic Ca2+,
and elicit muscle contraction.
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A-INTRODUCTION
Melatonin (N-acetyl-5-methoxytrypatmine), a derivative of 5-hydroxytryptomin
(serotonin) and an endogenous signal of darkness, is an important component of the body’s
internal time-keeping system and regulates diverse physiological processes such as diurnal
rhythm and gastrointestinal secretions and motility. Melatonin is also an effective
antioxidant, which scavenges free radicals and upregulates several antioxidant enzymes,
and anti apoptotic signaling molecules. Although melatonin is synthesized in many organs,
the major source of circulating melatonin is the pineal gland.
1- Melatonin Synthesis in Pineal Gland
Melatonin synthesis has been well investigated in the pineal gland. The amino acid
tryptophan, the primary precursor of melatonin, is absorbed frommet the circulation into
the gland [1]. The uptake process relies on transport mechanisms to cross the blood-brain
barrier [1]. Tryptophan then converts to 5-hydroxytryptophan by tryptophan-5hydroxylase, an enzyme found in mitochondria requiring a pteridine cofactor [1]. The
reaction is rate-limiting in the formation of serotonin, and this enzyme is limited to only
serotoninforming tissue. The rate of reaction is directly related to the amount of
tryptophan. Manual administration of large amounts tryptophan results in increased
formation of serotonin [1]. Decarboxylation of 5-hydroxytryptophan results in the
formation of serotonin (5-hydroxytryptamine), and is conducted by aromatic amino acid
decarboxylase, a cytoplasmic enzyme [1]. This enzyme has broad specificity and is widely
distributed in tissue requiring pyricoxal phosphate as a cofactor. Interestingly, constant
light appears to have a stimulatory effect on this process[1]. The next step in melatonin
synthesis is N-acetylation of serotonin. Arylalkylamine - N-acetyltransferase (AA-NAT),
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the enzyme responsible for this reaction, uses acetyl co-enzyme A as a cofactor. NAT is
present in many tissues and is likely a rate limiting step in melatonin synthesis [1]. The
final step is O-methylation of N-acetylserotonin by hydroxyindole-O-methyltrasnferase
(HIOMT). HIOMT transfers a methyl group from S-adenosyl methionine (SAM). \ AANAT and HIOMT are the key enzymes in melatonin synthesis [2].
Synthesis of melatonin is mainly seen at night and relates to the peak of AA-NAT
activity [3]. Recently, studies indicated that the main factor in regulating rhythmic and
light-induced changes in AA-NAT activity is the steady-state level of AA-NAT proteins,
which in turn reflects the balance of its synthesis and degradation [4]. These processes can
be regulated by distinct mechanisms and the significance of each of them is species
specific [5]. In humans, nocturnal synthesis of melatonin in the pineal gland is mainly
controlled by the central circadian clock, located in the hypothalamic suprachiasmatic
nucleus [6]. The circadian clock stimulates norepinephrine release from dense pineal
sympathetic fibers. Norepinephrine elevates the intracellular cAMP concentration via βadrenergic receptors and activates the cAMP-dependent protein kinase A, the essential
pathway for the regulation of AA-NAT synthesis and activity. In some mammals,
cAMP/protein kinase A protects the enzyme from degradation [7]. Therefore pinealocytes
constantly produce AA-NAT from continuously available AA-NAT mRNA. This protein
immediately undergoes proteasomal proteolysis during the day, in the absence of
noradrenergic stimulation. On the other hand, nocturnal elevation of the cAMP level
causes phosphorylation of AA-NAT via protein kinase protecting the enzyme from
degradation. Hence, increases of intracellular concentrations of AA-NAT are incongruence
with increases in enzyme activity. In rodents, the cAMP/protein kinase pathway induces
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transcriptional activation of the AA-NAT gene, the primary mechanism initiating
melatonin biosynthesis. In contrast, the importance of a transcriptional regulation of the
AA-NAT gene for melatonin production in humans is questionable [8]. Thus, analysis of
pineal tissue, taken from regular autopsies, showed significant rhythm for the correlation
between time of death and both AA-NAT activity and melatonin content, while AA-NAT
and HIOMT mRNA, as well as HIOMT activity showed no diurnal rhythm [8]. Although
dominant mechanisms for the generation of rhythmic melatonin synthesis in the human
pineal gland remain to be clarified, it is generally accepted that AA-NAT is alternating
melatonin synthesis with photoperiodic variation in duration, while the level of HIOMT
activity may tune the seasonal magnitude of hormone production [9, 10].
The rhythmical production of melatonin in the pineal gland accurately reflects
environmental light conditions; light exposure can significantly suppress nocturnal
melatonin secretion [11]. It has been reported that theses non-visual effects of light are
mediated by the retinohypothalamic tract, a distinct neural pathway mediating the
regulation of melatonin production by light [12, 13], which is initiated in the photoreceptor
system. The mammalian eyes perceive light and dark cycles which entrain the neural
activity of the suprachiasmatic nucleus, and alter the rhythmic secretion of melatonin from
the pineal gland [14]. However, it has been shown recently that rod and cone
photoreceptors of the retina do not participate in this pathway [15]. In effect, light at a
wavelength of 555 nm, providing a peak effect on the visual system [16], suppresses
melatonin synthesis in healthy humans approximately four times less than monochromatic
light at 505 nm [14].The visual photoreceptors conducting these effects remain unknown
[14]. Moreover, light-induced melatonin suppression and circadian entrainment have been
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demonstrated in humans with specific color vision deficiencies [17] or complete visual
blindness [18]. These studies suggest that melatonin biosynthesis is controlled, at least in
part, by photoreceptors that differ from the known visual photoreceptors [14]. Recent
studies on various vertebrate species identified several new molecules that may serve as
circadian photopigments. These pigments include opsin- based molecules (e.g. vertebrate
ancient opsin [19], melanopsin [20] and peropsin [21] ) as well as non-opsin molecules
(bilirubin [22] and cryptochrome [14, 23] ). Among these new photopigments, only
melanopsin has been discovered in the human neural retina [24]. Consequently, the diurnal
rhythmical production of melatonin is controlled by diverse mechanisms characterized by
highly adaptive plasticity regulatory mechanisms, most of which need to be further studied
and researched.

2- Melatonin Synthesis in Gastrointestinal Tract
In 1976, Raikhlin and Kvetnoy were one of the first to illustrate melatonin
production by serotonin-rich enterochromaffine (EC) cells in the gastrointestinal tract
acting as a paracrine molecule and hormone released into the portal vein [25]. Several
studies revealed that gastrointestinal tract substantially contributes to the peripheral blood
concentrations of melatonin. Considering the size of the gastrointestinal tract relative to
the pineal gland, it has been estimated that there is 400 times more melatonin in the gut
than in the pineal gland. Melatonin concentrations in the gut surpass levels in the blood
10-100 fold. Melatonin does not seem to be uniformly distributed and concentration varies
in various regions of the gut. In the digestive tract, melatonin has been identified using a
variety

of

methods

including

imuunocytochemical,
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chromatographic

and

radioimmuonomethods. Additionally, the melatonin synthesizing enzyme is reportedly
present in the gut as well as its synthesis from its precursor, serotonin, in EC cells of the
intestinal mucosa. Oral application of tryptophan (150 mg/kg), a known precursor to
melatonin, in rats causes a rapid elevation of circulating melatonin that was higher than
that acquired after administration of this amino acid [26]. Ligation of the portal vein led
elimination of the increment in plasma level of melatonin following the tryptophan
application. On the other hand, plasma level of melatonin remained unaffected upon
pinealectomy, suggesting the gastrointestinal tract by itself is the major source of
circulating melatonin after oral tryptophan application [26]. Melatonin is present in
gastrointestinal tract mucosa even under fasting conditions, yet this melatonin content in
the gastrointestinal tract increases exponentially following food intake and tryptophan
administration [26]. A number of other studies using immunohistochemistry and
radioimmunoassay techniques, validated by HPLC [27-30] confirmed the presence of
melatonin in gastrointestinal tract mucosa and indicated that enterochromaffine cells are
the main source of melatonin in human gastrointestinal tract aside from the pineal gland.
Similarly, Messner, who studied the distribution of melatonin in human hepatobiliarygastrointestinal tract, verified high concentration of melatonin in gastric and duodenal
mucosa with considerable amounts of this indole excreted into the bile [31].
Furthermore, extrapineal melatonin synthesis was more or less accepted when
melatonin-synthesizing

enzymes,

Nacetyltransferase

[35]

and

hydroxyindole-O-

methyltransferase [36] were detected in the gastrointestinal tract. Through the use of
transcriptionpolymerase chain reaction, the presence of both enzymes was confirmed [37].
Additional research confirmed there are fundamental differences between pineal-produced
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and GIT-produced melatonin. While pineal-produced melatonin acts mostly as an
endocrine substance, extrapineal-derived melatonin functions not only in endocrine, but
also in autocrine, paracrine and luminal capacity [38, 39]. There are also substantial
differences in the mode of secretion and response to food intake. Whereas nighttime levels
of melatonin in blood are mostly of pineal origin, day-time melatonin concentrations in
blood are produced mostly in the GIT [40]. Because of high levels of melatonin in the GIT
tissues and the large size of the GIT, the amount of melatonin in GIT is quite high. In
1994, Gerald Huether calculated that at any moment of the day or night, GIT contains at
least 400 times more melatonin than the pineal gland [41].

3- The Role of Melatonin in Circadian Rhythm
Melatonin signals time of day and time of year in mammals based on its pattern of
secretion, which defines ‘biological night.’ Animal studies revealed the fundamental role
of melatonin as a photoneuroendocrine transducer of information on day length.
Melatonin, by its changing duration of secretion at different day lengths (the longer the
night the greater the duration of hormone secretion), is probably a universal biological
signal indicating darkness [1, 42, 43]. Imposition of different day lengths in humans shows
a conserved photoperiodic response, and the evidence indicates that melatonin acts as a
biological signal for dawn and dusk in humans, as well as other species [44-47]. There is
evidence that the timing of melatonin secretion is closely associated with the timing of
sleep tendency [45, 48]. The timing of peak melatonin concentration coincides closely to
the nadirs of core body temperature, alertness and performance, clearance of plasma
triglycerides, and other night-time phenomena [49]. There is also evidence of melatonin’s
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influence on glucose homeostasis [50], the immune system [51], and cardiovascular
function [52].
Certainly humans sleep better during the appropriate period of melatonin secretion;
yet, is this due to melatonin itself, other factors, or to the whole circadian system working
in orchestra? In 1997 a study showed if melatonin is present at an abnormal phase during
the day, it is strongly associated with daytime naps [53]. The significance of melatonin
presence in sleep cycle can be seen by pharmacological suppression of daytime melatonin
production which diminishes daytime sleepiness, and treatment with exogenous melatonin
at night which restores night-time sleep [54, 55]. Pharmacological inhibition of
endogenous melatonin by atenolol heightens the human phase-shifting response to light
[56]. If given at an appropriate circadian phase, exogenous melatonin can act in
congruence with light and can also partially counteract light for phase-shifting [57, 58].
Therefore, melatonin’s presence modifies circadian responses. Based on these few
observations, it appears the presence of melatonin hinders rapid adaptation to phase-shift
as originally observed in rats [1] and that persons treated with b1 antagonists are likely to
suffer less jet-lag and to adapt more readily to night work than untreated individuals. It is
also reasonable to state that appropriate combinations of light and melatonin treatment
should be more efficient in the changing phase than either treatment alone; however, there
is little information on this subject. Although the evidence is not compelling, it has been
suggested that melatonin from the digestive tract may be secreted into the blood in a
circadian manner, as it is from the pineal gland. The circadian rhythm of gastrointestinal
tract melatonin depends on the type of digestion each species exhibits (e.g., diurnal vs.
nocturnal mon-gastric vs. ruminants).
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4- Melatonin receptor signaling
Two mammalian subtypes of G-protein coupled melatonin receptors have been
cloned and identified, MT1 and MT2 [59, 60]. While both share generally similar binding
characteristics for 125I-melatonin, the human MT2 receptor has a lower affinity
(Kd=160pmol/l) compared to the human MT1 receptor (Kd = 20 – 40 pmol/l) [61].
However both are of high affinity and the agonist binding is guanosine triphosphate
(GTP)-sensitive [60].
There has been discussion of a third melatonin binding site, “MT3,” yet it was later
characterized as the enzyme quinine reductase 2 [61]. Belonging to a group of reductastes
that participate in the protection against oxidative stress, enzyme quinine reductase
prevents electron transfer reactions of quinones. Additionally, functional and ligand
binding studies have shown the existence of low affinity (Kd in the 10 nm range)
melatonin membrane binding sites in the preoptic area of the hypothalamus and in the
medulla-pons in rats and hamsters [62-64]. Furthermore, melatonin interacts with
intracellular proteins such as calmodulin , calreticulin, or tubulin and antagonizes the
binding of Ca2+ to calmodulin [65-69]. These interactions are most likely related to some
of the physiological effects of melatonin but critical data regarding this point have yet to be
obtained.
MT1 and MT2 receptors are expressed both singly and together in various tissues
of the body [70, 71, 60]. Functional MT1 receptors have been localized in the SCN [72,
60], cerebellum [73], hippocampus [74], central dopaminergic pathways [75], ovary [76],
retina [77], coronary blood vessels and aorta [78, 79], liver and kidney [80], and the
gallbladder [81]. Melatonin MT2 receptors are more restrictively expressed, being found
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mainly in the brain, although their presence has also been detected in the lung, cardiac,
aortic and coronary tissue, myometrium and granulosa cells, immune cells, duodenum and
adipocytes [60]. The ‘‘MT3 receptor’’ is expressed in the liver, kidney, brain, heart, lung,
intestine, muscle and brown adipose tissue [82].
After binding to its membrane-bound receptors, melatonin changes the
conformation of the Alpha-subunit of specific intracellular G proteins. It regulates cell
function via intracellular second messengers such as cAMP, calcium ions, cGMP, DAG.
PKC, and Arachidonic acid; yet, the signal transduction pathways for melatonin receptors
appear to differ among varying tissues and cell types [83, 84]. Activation of G-Alpha I
through the binding of melatonin to MTR1 inhibits cAMP formation, PKA activity,
resulting in a decrease in CREB phosphorylation. Aside from the cAMP-dependent
cascade, MTR1 can mediate a PLC-dependent signal transduction cascade directly or
indirectly via G-BetaGamma subunits for phosphoinositide turnover and activate PKC.
Activation of MTR1 by melatonin also increases phosphorylation of MAPK or MEK1 and
MEK2 and ERK1/2. Interestingly, receptors themselves can modulate formation of
arachidonic acid and JNKs. Comprehensive regulation of activator protein-1a, a
transcription factor produced by the early gene products of c-Fos and c-Jun, has been
observed by the MAPK pathways, specifically ERK1, ERK2, and JNKs.
Furthermore, melatonin also has regulatory effects on several ion channels. Binding
of melatonin to MTR1 receptors potentiates vasoconstriction via blocking calciumactivated potassium channels in smooth muscle cells. The obstruction of this channel may
be due to a decrease in cAMP and in phosphorylation of the calcium-activated potassium
channel by PKA. In addition, melatonin directly vasoconstricts cerebral arteries through
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inhibition of calcium-activated potassium channels. MTNR1As also couple to the GIRK
(G-protein-activated Inward Rectifier Potassium)/Kir 3 channels.
Activation of MTNR1Bs modulates levels of cAMP and cGMP. Like the case with
MTNR1A, activation of the MTNR1B by melatonin inhibits cAMP formation.
Additionally, MTNR1B activation leads to the inhibition of cGMP formation. Inhibition
occurs through proteins upstream of the Guanylyl Cyclase such as NOS. In the SCN,
melatonin increases PKC activity through activation of GN-AlphaQ, which activates the
PLC and DAG pathway. MT1 activation of Gq proteins has been shown to mediate
calcium mobilization via activation of the inositol-specific phospholipase C (PLC) [85]
and activation of protein kinase C [86]. The melatonin receptors also serve as the
mediators of several other physiological responses to melatonin. These responses include
(i) phase advance of circadian rhythms in the isolated SCN, which involves PKC
activation; (ii) enhancement of cell-mediated and humoral immunity; (iii) inhibition of
leukocyte rolling in the microvasculature; and (iv) inhibition of proliferation of human
choriocarcinoma cells, probably by delay of the G1 to S cell cycle transition. Furthermore,
activation of MTR2 decreases the expression of the glucose transporter GLUT4 that in turn
decreases glucose uptake in human brown adipocytes, modulates neuronal activity in the
hippocampus, and mediates vasodilation in arterial beds.

5- Effects of Melatonin in Gastrointestinal Tract
Melatonin has a special importance in the gastrointestinal tract because the
enterocromaffin cells of the gut are the main source of extrapineal melatonin. Melatonin
modulates gastrointestinal motility, transport of ion and electrolytes and postprandial
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sequential activation of gastrointestinal tract. Numerous studies demonstrated that
melatonin exerts protective and healing effects in gastric ulcers and experimental colitis.
Direct antioxidative effect and release of endogenous prostaglandins are associated with
these effects [115]. Melatonin administration at pharmacological doses decreases free
radical formation and leads to substantial recovery of the major antioxidative enzymes
[39]. In addition, melatonin has pleiotropic effects on the immune system causing an
enhancement of both innate and cellular immunity, which underlies its immunomodulatory
role in inflammation [80].

Therapeutic potential of melatonin in the recovery of

gallbladder neuromuscular function during acute cholecystitis and aging was also reported,
but the exact cellular mechanism through which melatonin exerts its effects in the
gallbladder are not known [116, 117].
Many factors released in the gut modulate motility and secretion. Melatonin plays a
particularly important role in modulation of gastrointestinal functions reflecting the cyclic
pattern of food intake. Binding to selective receptors expressed on the smooth muscles and
myenteric plexus cells of gastrointestinal tract allows melatonin to have a significant
influence on gastrointestinal motility. The basal mechanism underlying the gastrointestinal
smooth muscle contraction is the cyclic generation of the electrical current.
The myoelectric activity of gastrointestinal tract is comprised of two kinds of
potentials – slow way and spiked activity coordinated in the myoelectric migrating
complex (MMC). Internal and external autonomic nerves modulate the Interstitial Cajal’s
pacesetter cells (ICC) [87]. ICC produces the basic electrical rhythm (BER) which is
simply the generation of slow waves determining bowel motility.
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Frequency of the slow wave determines the contraction/relaxation activity of the
gastrointestinal smooth muscle. The intestinal pacemaker is located in the duodenal bulb,
near the pylorus, and is independent from the gastric electrical activity pacemaker. The
duodenal region is where the frequency and velocity of slow waves are greatest and
decreases caudally [88, 89]. In the rat, the duodenal slow wave frequency ranges from 20
to 40 cycles per minute and has greater amplitude and plateau than the jejunum.
Furthermore, the BER amplitude ranges from -55 to -35 mV [90]. This electrical activity
can be used as an indicator of gastro duodenal coordination because it is greatly influenced
by a number of paracrine and neurocrine factors. Melatonin in the fasted state induces
dramatic reduction of the irregular spike activity (ISA) on the entire intestine including
phase III of the MMC. Periodicity of MMC length decreased by 50% [91]. This study
revealed effects of melatonin on myoelectric activity provide strong evidence that
melatonin relaxes the bowel by acting mostly on phasic contractions.
The gastrointestinal tract motility depends on a dark-light cycle. Namely, motility
is activated more during daylight than during the dark period. The latest reports provided
data that melatonin plays an important role in regulation of the gastrointestinal motility. In
fact, it has been documented that postprandial motor response is shorter in the dark phase
than in the light phase and this effect can be reversed by melatonin antagonist [92].
There is belief that endogenous melatonin act on pre and postprandial intestinal
motility at night and this effect has also been observed with exogenously administered
hormone. Additionally, there are findings that melatonin reinforce cyclic pattern of MMC
but inhibit occurrence of irregular spike activity [91]. There is also apparent interaction
between melatonin and CCK in terms of motility. Melatonin was found to reduce the
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duration of CCK stimulatory effects on gastrointestinal smooth muscle [92]. There is
speculation that melatonin is released to the lumen of proximal bowel in response to food
intake and travels to the distal part. This may in part explain why the MMC pattern first
reappears in the distal part of the bowel in the end period of satiety.
However, present reports are inconsistent in the matter of the melatonin’s role on
gut motility. Martín at al. suggests that melatonin release induced by lipid infusion
alleviate inhibitory effect of lipid related ileal break suggesting that melatonin plays a
modulatory role on gastric emptying [93]. These results correspond partially with reports
of Drago at al. who observed that small doses of melatonin accelerate the intestinal transit
in rats. High doses reversed stimulatory effects of lower doses of melatonin indicating that
intestinal melatonin receptors might mediate melatonin effects. Moreover, administered
intraperitoneally melatonin increased intestinal myoelectrical activity. This effect was
reversed by the competitive receptor antagonist, Luzindole, and seems to be mediated by
peripheral receptors [94].

6- Gastric Motility
Gastric smooth muscle activity is responsible for two fundamental patterns of
motility, mixing and propulsion. The formation of chyme, a liquefied state of partly
digested food, is formed through a process of mixing, crushing, and grinding of ingested
food. Subsequently, smooth muscle activity forces the chyme through the pyloric canal,
into the small intestines, a process known as gastric emptying. Based on motility pattern,
the stomach can be divided into two regions harboring either tonic contraction or phasic
contraction.
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The proximal stomach, composed of primarily the fundus, shows low frequency,
sustained contractions that are responsible for generating a basal pressure within the
stomach. Importantly, these tonic contractions also generate a pressure gradient from the
stomach to small intestine and are therefore responsible for gastric emptying. Swallowing
of food and consequent gastric distention inhibits contraction of this region of the stomach,
allowing it to increase in volume and form a large reservoir without a significant increase
in pressure. This phenomenon is called "adaptive relaxation."
The distal stomach, comprised of primarily the antrum, develops strong peristaltic
waves of contraction that increase in amplitude as they propagate toward the pylorus.
These powerful contractions constitute a very effective gastric grinder; they occur about 3
times per minute in people. There is a pacemaker in the smooth muscle of the greater
curvature that generates rhythmic slow waves from which action potentials and hence
peristaltic contractions propagate. Gastric distention strongly stimulates this type of
contraction, accelerating liquefaction and gastric emptying. The pylorus is functionally part
of this region of the stomach. When the peristaltic contraction reaches the pylorus, its
lumen is effectively degraded; chyme is thus delivered to the small intestine.
A study by Kasimay et al. [95] indicated that melatonin inhibit gastric motility by
interacting with serotonin receptors present on the on vagal afferent fibers via vago-vagal
inhibitory reflexes. Storr et al. [96, 97] has demonstrated the expression of MT1, but not
MT2 receptors using RNA isolated from the muscle layers of rat stomach and intestine.
Addition of melatonin to isolated muscle strips inhibited non-aderenergic and noncholinergic mediated relaxations, but had an effect on exogenous nitric oxide (NO)mediated relaxation.

In synaptosomal preparations melatonin inhibited basal nNOS
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activity. These results suggest that melatonin actions are mediated by inhibition of nNOS
activity via MT1 receptors. In addition to its effect on basal nNOS activity, melatonin was
shown to suppress nNOS express in rat hypoglassal nucleus following peripheral nerve
injury [98], nNOS activity in rat striatum [99] and eNOS activity in rat cerebellum [100].
These studies indicate the difficulties in identifying the signaling pathways
activated by melatonin in vivo and in innervated in vitro preparations. The effect of
melatonin may vary in different specific regions of the gut depending on whether the
activated receptor is present predominantly on smooth muscle cells or enteric neurons.
Transmitters released from the enteric neurons, in turn, modulate the intrinsic electrical and
mechanical activity of the gastrointestinal smooth muscle. To avoid the confounding
effects of neural activation by melatonin, the present study has characterized the receptors
for melatonin and the signaling pathways to which these receptors are coupled in freshly
dispersed and cultured smooth muscle cells of the gut.
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B- METHODS

1- Collection of tissue
Rabbits were sacrificed by injection of Euthasol (100 mg/kg body weight) into the
ear vein. The stomach was rapidly removed, emptied of its contents and placed in a cold
smooth muscle buffer with the following composition: NaCl 120 mM, KCl 4 mM,
KH2PO4 2.6 mM, CaCl2 2.0 mM, MgCl2 0.6 mM, HEPES (N-2-hydroxyethylpiperazineN’ 2-ethanesulfonic acid) 25 mM, glucose 14 mM, and essential amino mixture 2.1%
(pH7.4)

2- Preparation of dispersed gastric smooth muscle cells
The antrum was separated from the rest of the stomach and the mucosal layer was
removed by sharp dissection. Smooth muscle cells from the circular muscle layer of the
antrum were isolated by sequential enzymatic digestion of muscle strips, filtration, and
centrifugation as described previously [101-108]. The antrum was cut into thin slices
using a Stadie-Riggs tissue slicer and then the slices were incubated for 30 min in a
smooth muscle buffer at 31°C containing 0.1% collagenase (300 U/ml) and 0.01%
soybean trypsin inhibitor (w/v). The tissue was continuously gassed with 100% oxygen
during the entire isolation procedure. The partly digested tissues were washed twice with
50-ml of collagenase-free smooth muscle buffer and the muscle cells were allowed to
disperse spontaneously for 30 min in collagenase-free medium. Cells were harvested by
filtration through 500 µm Nitex and centrifuged twice at 350 g for 10 min to eliminate
broken cells and organelles. The cells were counted in a hemocytometer and it is
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estimated that 95% of the cells excluded trypan blue. The experiments were done within
2-3 h of cell dispersion.

3- Preparation of cultured gastric smooth muscle cells
Dispersed muscle cells isolated from the antrum were resuspended in DMEM
containing penicillin (200 U/ml), streptomycin (200 µg/ml), gentamycin (100 µg/ml),
amphotericin B (2.5 µg/ml) and 10% fetal bovine serum (DMEM-10). The muscle cells
were plated at a concentration of 5 X 105 cells/ml and incubated at 37°C in a CO2
incubator.

DMEM-10 medium was replaced every three days for 2-3 weeks until

confluence was attained. The muscle cells in confluent primary cultures were trypsinized
(0.5 mg trypsin/ml), re-plated at a concentration of 2.5 X 105 cells/ml and cultured under
the same conditions. All experiments were done on cells in the first passage. Previous
studies have determined the purity of cultured muscle cells with smooth muscle-specific
γ-actin [109]. Cultured muscle cells were starved in serum-free medium for 24 hours
before each use.

4- Expression of MT1 in smooth muscle cells by RT-PCR
Total RNA was isolated from smooth muscle cells with TRIzol® reagent
(Invitrogen) and treated with TURBO DNase (Ambion). RNA from each preparation was
reversely transcribed using the SuperScript™ II system containing 50 mM Tris–HCl (pH
8.3), 75 mM KCl, 3 mM MgCl2, 10 mM dithiothreitol (DTT), 0.5 mM deoxynucleoside
triphosphates (dNTP), 2.5 µM random hexamers and 200 units of reverse transcriptase in
a 20 µl reaction volume. The reactions were carried out at room temperature for 10 min
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and at 42°C for 50 min, and terminated by heating at 70°C for 15 min. Three µl of the
reversely transcribed cDNA was amplified in a final volume of 50 µl by PCR in standard
conditions (2 mM MgCl2, 200 µM dNTP, 2.5 units Taq polymerase) with specific primers
designed based on conserved sequences in human, rat and mouse cDNAs: MT1
(Forward:TTCATTGGTCTTGCAGTGGCCTCAG; Reverse:GAACATCCTTGCTGTA
CACATTGAG)

and

MT2:

(Forward:

TTGTCCACCGTGCTCATCGTCACCAC;

Reverse:TGGCCTTGCAATGCGCCTCTCCCAG). PCR for MT1 and MT2 receptors
was performed for 30 cycles. For each experiment, a parallel control without reverse
transcriptase was processed. The amplified PCR products were analyzed on 1.5% agarose
gel containing 0.1 µg/ml ethidium bromide [109].

5- Expression of MT1 in smooth muscle cells by Western Blot
Muscle cells were solubilized in Triton X-100-based lysis buffer plus protease and
phosphatase inhibitors (100 µg/ml PMSF, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 30 mM
sodium fluoride and 3 mM sodium vanadate). After centrifugation of the lysates at 20000
g for 10 min at 4 °C, the protein concentrations of the supernatant were determined with a
Dc protein assay kit from Bio-Rad. Equal amount of proteins were fractionated by
SDS/PAGE, and transferred on to nitrocellulose membrane. Blots were blocked in 5%
(w/v) non-fat dried milk/TBS-T [tris-buffered saline (pH 7.6) plus 0.1% Tween-20] for 1
h and then incubated overnight at 4 °C with various primary antibodies in TBS-T plus 1%
(w/v) non-fat dried milk. After incubation for 1 h with horseradish-peroxidase-conjugated
corresponding secondary antibody (1:2000; 10 µg/ml, Pierce) in TBS-T plus 1% (w/v)
non-fat dried milk, immunoreactive proteins were visualized using SuperSignal Femto
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maximum sensitivity substrate kit (Pierce). All washing steps were performed with TBST. The protein bands were identified by enhanced chemiluminescence reagent [110-112].

6- Identification of G proteins coupled to MT1
G proteins selectively activated by melatonin was identified from the increase in
Gα binding to the [35S]GTPγS (5’-O-3-thiotriphosphate) as described previously [106108] . Ten ml of muscle cell suspension (3 X 106 cells/ml) were homogenized in 20 mM
HPES medium (pH 7.4) containing 2 mM MgCl2, 1 mM EDTA and 2 mM DTT. After
centrifugation at 30,000 g for 15 min, the crude membranes were solubilized for 60 min at
4 °C in 20 mM HEPES medium (pH 7.4) containing 2 mM EDTA, 240 mM NaCl, 0.5%
CHAPS (3-[(3-cholamidopropyl) dimethylammonio]-1-pro-panesulfonate), 2 mM PMSF,
20 µg/ml aprotinin, and 20 µM leupetin. The membrane were incubated for 20 min at
37°C with 60 nM [35S]GTPγS in the presence or absence of melatonin (1 µM) in a
solution containing 10 mM HEPES (pH 7.4), 100 µM EDTA and 10 mM MgCl2. The
reaction was terminated with 10 volumes of 100 mM of Tris-HCl medium (pH 8.0)
containing 10 mM MgCl2, 10 mM NaCl and 10 µM GTP, and the mixture was placed in
wells precoated with specific antibodies to Gαq, Gαi1, Gαi2, Gαi3, and Gαs. Coating with
G protein antibodies (1:1000) was done after the wells were first coated with anti-rabbit
IgG (1:1000) for 2 h on ice. After incubation for 2 h on ice, the wells were washed three
times with phosphate buffer saline solution (PBS) containing 0.05% Tween-20 and the
radioactivity from each well was counted by liquid scintillation.

The amount of

[35S]GTPγS bound to the activated Gα subunit was expressed as counts per minute (cpm)
per milligram of protein.
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7- Phosphoinositide(PI)-specific phospholipase C (PLC-β
β ) activity
PI hydrolysis (PLC-β activity) was determined in freshly dispersed or cultured
smooth muscle cells by measuring the formation of inositol phosphates using ionexchange chromatography as previously described [101-103]. Ten ml of cell suspension
(2 x 106 cells/ml) were labeled with myo-[3H] inositol (15 µCi/ml) for 90 min at 31 °C.
Then cells were centrifuged at 350 g for 10 min to move excess [3H]inositol and
resuspended in 10 ml of fresh medium. Lithium was added to a final concentration of 10
mM and the suspension was incubated for another 10 min. Melatonin was added to 0.5
ml of cell suspension and the mixture was incubated in a shaking water bath for 1 min.
Cultured smooth muscle cells were labeled with [3H]myo-inositols (0.5 µCi/ml) for 24 h
in inositol-free DMEM medium. The cultures were washed with phosphate-buffered
saline (PBS) and treated with anandamide (1 µl) for 1 min in HEPES medium (pH 7.4).
The reaction was terminated by the addition of chloform:methanol:HCl (50:100:1 v/v/v).
After chloroform (310 µl) and water (310 µl) were added, the samples were vortexed and
the phases were separated by centrifugation at 1000 g for 15 min. The upper aqueous
phase was applied to a column containing 1 ml of 1:1 slurry of Dowex AG-1 X8 resin
(100-200 mesh in formate form) and distilled water.
The column was washed with 10 ml of water followed by 10 ml of 5 ml sodium
tetraborate-60 mM ammonium formate to remove [3H]glycerophosphoinositol. Total
inositol phosphates were eluted with 6 ml of 0.8 M ammonium formate-0.1 M formic
acid. The eluates were collected into scintillation vials and counted in gel phase after
addition of 10 ml of scintillant. The results were expressed as counts per minute per mg
protein.

27

8- Measurement of Ca2+ release
Melatonin-induced increase in [Ca2+]i was measured by fluorescence in single
smooth muscle cell loaded with fluorescent Ca2+ dye fura 2 [113]. Dispersed muscle cells
were plated on coverslips for 12 h in DMEM. After being washed with PBS, the cells
were loaded with 5 µM fura 2-AM for 1 h at room temperature. The cells were visualized
through a x40 objective (ZEISS; 0.9 NA) with a Zeiss Axioskop 2 plus upright
fluorescence microscope and imaged with a setup consisting of a charge coupled device
camera (Imago, TILL Photonics, Applied Scientific Instrumentation, Eugene, OR)
attached to an image intensifier. The cells were alternately excited at 380 and 340 nm.
The background and autofluorescence were corrected from images of a cell without the
fura 2. Results are expressed as increased in 340/380 ratio.

9- Measurement of contraction in dispersed smooth muscle cells
Contraction in freshly dispersed gastric circular smooth muscle cells was
determined by scanning micrometry as previously described [101-113]. An aliquot (0.4
ml) of cells containing approximately 104 cells/ml was treated with 1 µM melatonin in the
presence and absence of the PLC β inhibitor U73122 (10 µM) for 30 s and the reaction
was terminated with 1% acrolein at a final concentration of 0.1%. Acrolein kills and fixes
cells without affecting the cell length. The resting cell length was determined in control
experiments in which muscle cells were incubated with 100 µl of 0.1% bovine serum
albumin without the agonists.

The mean lengths of 50 muscle cells treated with various

agonists was measured by scanning micrometry and compared with the mean lengths of
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untreated cells. The contractile response was expressed as the percent decrease in mean
cell length from control cell length.

10-

Materials

Melatonin was purchased from Bachem (Torrance, CA). [3H]myo-inositol were
obtained from PerkinElmer Life Sciences, (Boston, MA). Polyclonal antibodies to MT1,
MT2, Gαi1, Gαi2, Gαi3, Gαs, and Gαq were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Western blotting, Dowex AG-1 X 8 resin (100-200 mesh in formate
form), chromatography material and protein assay kit, 15% Tris-HCl Ready Gels were
obtained from Bio-Rad Laboratories (Hercules, CA); collagenase and soybean trypsin
inhibitor were obtained from Worthington Biochemical (Freehold, NJ).

RT- PCR

primers were purchased from Integrated DNA technologies, Inc (Coralville, IA). Fura2/AM was obtained from Molecular Probes (Carlsbad, CA). Effectene Transfection
Reagent, QIAEX®II Gel extraction Kit and QIAprep®Spin Miniprep Kit were obtained
from QIAGEN Sciences, Maryland; PCR reagents were obtained from Applied
Biosystems, Roche; SuperScriptTM II Reverse Transcriptese and TOPO TA Cloning® Kit
Dual Promoter were obtained from Invitrogen, CA; EcoR I was obtained from New
England Bio Labs; Dulbecco’s modified Eagle’s medium (DMEM) was obtained from
Fisher Scientific. All other chemicals were obtained from Sigma, St. Louis, MO.
New Zealand white rabbits (weight: 4-5 lbs) were purchased from RSI
Biotechnology, Clemmons, NC and were housed in the animal facility administered by
the Division of Animal Resources, Virginia Commonwealth University. Animals were
killed by sodium pentobarbital overdose (100 mg/kg), as approved by the Institutional
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Animal Care and Use Committee of the Virginia Commonwealth University.

All

procedures were conducted in accordance with the Institutional Animal Care and Use
Committee of the Virginia Commonwealth University.

11-

Statistics Analysis

The results were expressed as means + S.E. of n experiments and analyzed for
statistical significance using Student’s t-test for paired and unpaired values.
experiment was done on cells obtained from different animals.

Each

Differences among

multiple groups were tested by using ANOVA and checked for significance using
Fisher’s protected least significant difference test.
considered significant.
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A probability of P< 0.05 was

C- RESULTS

1- Expression of MT1 in gastric smooth muscle
Specific primers for MT1 and MT2 were designed based on the conserved
sequences in human, rat and mouse cDNAs. MT1, but not MT2 receptors were detected
by RT-PCR on RNA extracted from cultures of gastric smooth muscle cells in first
passage (Fig. 1). PCR product of the expected size (225 bp) was obtained. The isolated
partial nucleotide sequence of rabbit MT1 was similar to the corresponding amino acid
sequences of human (86%) and rat (83%) (Fig. 2). As shown previously [109], the use of
confluent cultures of smooth muscle in first passage ensured the absence of neural,
endothelial, or interstitial cell contaminants and the presence of PCR product in cultured
muscle cells demonstrate the expression of MT1 mRNA in smooth muscle cells.
Expression of MT1 and MT2 receptor protein was examined by western blot
analysis using selective antibody to MT1 or MT2. The results demonstrate the expression
of MT1 of predicted size (36 kDa) in the homogenates of isolated smooth muscle cells
(Fig 1). Expression of MT2 was not detected in the homogenates of dispersed gastric
muscle cells.

2- Identification of G proteins coupled to MT1 receptors in smooth muscle
Studies in various tissues and cell lines suggest that MT1 receptors are coupled to
activation of G proteins, but the specific G proteins coupled to MT1 receptors in smooth
muscle has not been identified. Muscle cells membranes were incubated with [35S]GTPγS
(60 nM) in the presence or absence of melatonin (1 µM) and the aliquots were added to
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wells precoated with different Gα antibodies; an increase in the binding of [35S]GTPγS
complexes to a specific Gα antibody reflected the activation of the corresponding G
protein. In some experiments low concentrations of GTPγS stimulated binding of
[35S]GTPγS to Gαi2, Gαq and Gαs.

However, incubation of muscle membranes with

melatonin in the presence of low concentrations GTPγS caused a significant increase in
the binding of [35S]GTPγS selectively to Gαq (392±45% increase above basal levels, p<
0.001, n=8), but not to Gαi1, Gαi2, Gαi3, or Gαs (Figs. 3-7). These results suggest that
MT1 receptors are preferentially coupled to activation of Gq in gastric smooth muscle.
Previous studies in gastric smooth muscle disclosed the presence of Gαi1, Gαi2, Gαi3,
Gαs, and Gαq and activation of G proteins in smooth muscles is receptor specific:
somatostatin sstr3 receptors are coupled to Gi1, opioid δ receptors are to Gi2, muscarinic
m2 receptors are coupled to activation of Gi3, muscarinic m3 receptors are coupled to
expression of Gq and VPAC2 receptors are coupled to Gs [106, 107, 111, 114].

3- Signaling pathways activated by MT1 in gastric smooth muscle
Previous studies in smooth muscle have shown that activation of Gq by excitatory
neurotransmitters such as acetylcholine and substance P results in the stimulation of
phosphoinositide(PI)-specific phospholipase C (PLC-β) activity, generation of inositiol
1,4,5-trisphosphate (IP3) and IP3-dependent Ca2+ release leading to smooth muscle
contraction. The effector enzyme stimulated by Gq proteins coupled to MT1 receptors
was examined by measurements of inositol formation in response to melatonin in cells
labeled with [3H]myo-inositol. As expected from the activation of Gq, incubation of
muscle cells with melatonin for 60 s caused an increased in inositol formation in a
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concentration-dependent fashion with an IC50 of 4±1 nM (Fig. 8). The increase was
significant at 10 nM (1473±104 cpm/mg protein above basal levels of 896±101cpm/mg
protein, p<0.01, n=4) and a maximal increase was obtained at 1 µM (7142±351 cpm/mg
protein/mg protein above basal levels, p<0.001, n=4). The extent of stimulation of PLC-β
activity with melatonin was similar to that obtained with other contractile agonists such as
acetylcholine or substance P in gastric smooth muscle cells [111].
The G protein involved in the activation of PLC-β activity in response to
melatonin was obtained by expression of Gα minigenes in cultured smooth muscle cells.
The synthetic peptide corresponding to the COOH terminus of Gα subunits selectively
antagonized G protein activation by blocking receptor-G protein interaction [112, 113].
Minigene plasmid constructs that encode COOH-terminal peptide sequence of Gαi and
Gαq were expressed to selectively block Gi and Gq activation, respectively. Treatment of
cultured muscle cells with melatonin (1 µM) caused a significant increase in PLC-β
activity and the extent of stimulation was closely similar to that obtained in freshly
dispersed smooth muscle cells (5867±980 cpm/mg protein above basal levels in cultured
smooth muscle cells and 6245±1005 cpm/mg protein above basal levels in freshly
dispersed smooth muscle cells). Expression of Gαq minigene blocked PLC-β activity in
response to melatonin (Fig. 9). In contrast, expression of Gαi minigene had no effect on
PLC-β activity (Fig. 9). The results suggest that MT1 receptor coupled to activation of
PLC-β activity via Gαq and is consistent with the selective activation of Gαq by
melatonin.
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Activation of PLC-β results in the generation of inositol 14,5-trisphosphate (IP3)
and IP3-dependent Ca2+ release from intracellular sarcoplasmic reticulum stores [114].
Consistent with the activation of Gq and stimulation of PLC-β activity, addition of
melatonin to cells loaded with fura-2 resulted in an increase in cytosolic Ca2+ (Fig. 10).
The increase in Ca2+ was not affected by removal of extracellular Ca2+ suggesting that the
increase is due to release of Ca2+ from intracellular stores.
Stimulation of PLC-β activity and increase in intracellular Ca2+ by contractile
agonists in smooth muscle leads to muscle contraction. The functional significance of
MT1 receptor-mediated stimulation of PLC-β activity and increase in cytosolic Ca2+ was
examined by measurements of muscle contraction by scanning micrometry. Contraction
was measured as decrease in muscle cell length in response to melatonin compared to
control cell length. Treatment of muscle cells with 1 µM melatonin caused 25±42%
(p<0.001, n=6) decrease in cell length (control cell length 125±4 µm) (Fig. 11).

The

extent of contraction induced by melatonin is similar to that obtained with other
contractile agonists such as acetylcholine, substance P, ATP, sphingosine 1-phosphate
(27±3% to 32±4% decrease in cell length) in smooth muscle cells [111, 112, 114].
Melatonin-induced contraction was blocked by the selective PLC-β inhibitor, U-73122
(10 µM) (5±3% contraction in the presence of U73122) (Fig. 11). These results suggest
that contraction in response to melatonin was mediated via activation of PLC-β and
generation of IP3 and IP3-dependent Ca2+ release.
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In summary,

1. MT1, but not MT2 receptors are expressed in gastric smooth muscle cells.
2. MT1 receptors are coupled to activation of Gq, but not Gs, Gi1, Gi2 and Gi3
3. Melatonin induced activation of PI-specific PLC-β activity in a concentrationdependent manner in freshly dispersed muscle cells.
4. Melatonin also stimulated PLC-β activity in cultured smooth muscle cells and the
stimulation was blocked in cells expressing Gαq minigene, but not Gαi minigene
5. Melatonin induced an increase in cytosolic Ca2+ in the absence of extracellular Ca2+.
6. Melatonin elicited muscle contraction and the response is similar to other contractile
agonists such as acetylcholine, as shown previously. Contraction was inhibited by the
PLC-β inhibitor U73122 consistent the stimulation of PLC-β activity and increase in
intracellular Ca2+ by melatonin.
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Figure 1: Expression of MT1 receptors in gastric smooth muscle cells. A). Total
RNA isolated from cultured (first passage) rabbit gastric muscle cells was reverse
transcribed, and cDNA was amplified with specific primers for MT1 or MT2.
Experiments were done in the presence or absence of RT. PCR product with predicted
size (226) was obtained in the presence of RT only with primers for MT1. B) Western
blot analysis of lysates prepared from dispersed smooth muscle cells (lane 1) and cultured
gastric smooth muscle cells (lane 2) of rabbit and cultured gastric smooth muscle cells of
rat (lane 3). Proteins were probed with polyclonal antibodies to MT1 (1:1000) or MT2
(1:1000). A protein band corresponding to 36 kDa was obtained with only MT1 antibody.

36

Figure 1

RT-PCR
MW + RT

Western Blot
1

- RT

37

2

3

Figure 2.

Partial nucleotide sequence of MT1-R receptors from rabbit gastric

muscle cells. The RT-PCR product from cultured rabbit gastric smooth muscle cells was
sequenced.
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Figure 2
TGC CAT TTG CTG GGC TCC TCT AAA CTT CAT TGG TCT TGC AGT GGC
CTC AGA CCC TGT CAG CAT GGT ACC CAG AAT CCC AGA GTG GCT GTT
TGT GGC TAG TTA TTA CAT GGC AAT ATT TCA ACA GCT GTC TCA ATG
CAA TCA TAT ATG GAC TAC TGA ACC AGA ATT TCC GGG AGG AAT ATA
GAA GAA TTA TAA TCT CAA TGT GTA CAG CAA GGA TGT TCT TTG TGG
A
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Figure 3.

Activation of Gi1 proteins by melatonin in dispersed muscle cells.

Membranes were isolated from dispersed gastric muscle cells and incubated with
[35S]GTPγS for 20 min in the presence or absence of melatonin (1 µM). Aliquots were
added to wells coated with Gαi1 antibody for 2 h and bound radioactivity from each well
was counted by liquid scintillation. The amount of [35S]GTPγS bound to the activated Gα
subunit was expressed as counts per minute (cpm) per milligram of protein. Melatonin
did not induce significant increase in the binding of [35S]GTPγS.Gα complexes to wells
coated with Gαi1 antibody. Values are mean±SEM of 4 experiments.
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Figure 4. Activation of Gi2 proteins by melatonin in dispersed muscle cells.
Membranes were isolated from dispersed gastric muscle cells and incubated with
[35S]GTPγS for 20 min in the presence or absence of melatonin (1 µM). Aliquots were
added to wells coated with Gαi2 antibody for 2 h and bound radioactivity from each well
was counted by liquid scintillation. The amount of [35S]GTPγS bound to the activated Gα
subunit was expressed as counts per minute (cpm) per milligram of protein. Melatonin
did not induce significant increase in the binding of [35S]GTPγS.Gα complexes to wells
coated with Gαi2 antibody. Values are mean±SEM of 4 experiments.
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Figure 5.

Activation of Gi3 proteins by melatonin in dispersed muscle cells.

Membranes were isolated from dispersed gastric muscle cells and incubated with
[35S]GTPγS for 20 min in the presence or absence of melatonin (1 µM). Aliquots were
added to wells coated with Gαi3 antibody for 2 h and bound radioactivity from each well
was counted by liquid scintillation. The amount of [35S]GTPγS bound to the activated Gα
subunit was expressed as counts per minute (cpm) per milligram of protein. Melatonin
did not induce significant increase in the binding of [35S]GTPγS.Gα complexes to wells
coated with Gαi3 antibody. Values are mean±SEM of 4 experiments.
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Figure 6.

Activation of Gs proteins by melatonin in dispersed muscle cells.

Membranes were isolated from dispersed gastric muscle cells and incubated with
[35S]GTPγS for 20 min in the presence or absence of melatonin (1 µM). Aliquots were
added to wells coated with Gαs antibody for 2 h and bound radioactivity from each well
was counted by liquid scintillation. The amount of [35S]GTPγS bound to the activated Gα
subunit was expressed as counts per minute (cpm) per milligram of protein. Melatonin
did not induce significant increase in the binding of [35S]GTPγS.Gα complexes to wells
coated with Gαs antibody. Values are mean±SEM of 4 experiments.
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Figure 7.

Activation of Gq proteins by melatonin in dispersed muscle cells.

Membranes were isolated from dispersed gastric muscle cells and incubated with
[35S]GTPγS for 20 min in the presence or absence of melatonin (1 µM). Aliquots were
added to wells coated with Gαq antibody for 2 h and bound radioactivity from each well
was counted by liquid scintillation. The amount of [35S]GTPγS bound to the activated Gα
subunit was expressed as counts per minute (cpm) per milligram of protein. Melatonin
induced significant increase in the binding of [35S]GTPγS.Gα complexes to wells coated
with Gαq antibody. Values are mean±SEM of 4 experiments. ** P< 0.001
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Figure 8. Concentration-response curve for the stimulation of melatonin-induced
PLC-β
β activity in dispersed gastric muscle cells.

Phosphoinositide-specific (PI)

hydrolysis (PLC-β activity) in response to melatonin was measured in muscle cells
labeled with myo-[3H]inositol. Freshly dispersed muscle cells were treated for 60 s with
different concentrations of melatonin and PLC-β activity was measured as increase in
water-soluble [3H]inositol formation. The results are expressed as [3H]inositol phosphate
formation in counts per minute (cpm) per mg protein above basal levels (cpm/mg
protein). Values are means±SEM of 4 experiments. ** P< 0.01
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Figure 9.

Inhibition of melatonin-stimulated PLC-β activity by Gα
αq minigene

Cultured gastric muscle cells labeled with myo-[3H]inositol and expressing Gαq
minigene, Gαi minigene, or control vector were treated with melatonin (1 µM) for 60 s.
Total [3H]inositol phosphates were separated by ion-exchange chromatography. PLC-β
activity stimulated by melatonin was abolished in cells expressing Gαq minigene, but was
not affected in cells expressing Gαi minigene. Results are expressed as total [3H]inositol
phosphate formation in cpm/mg protein. Values are means ± S.E. of four experiments.
** Significant inhibition from control response (P<0.01)
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Figure 10.

Melatonin-induced increase in cytosolic Ca2+ in single muscle cells.

Muscle cells were loaded with 5 µM fura-2 and treated with 1 µM melatonin in the
absence of extracellular Ca2+. The cells were alternately excited at 380 nm and 340 nm.
The background and autofluorescence were corrected from images of a cell without the
fura 2.

Results are expressed as 340/380 ratio and an increase in ratio reflects an

increase in cytosolic Ca2+. The figure shows results obtained from 38 cells.
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Figure 11. Melatonin-induced muscle contraction in dispersed gastric muscle cells.
Contraction of muscle cells was measured as decrease in basal cell length in response to
melatonin (1 µM). Muscle cells (0.5 ml cell suspension) were treated with melatonin (1
µM) in the presence or absence of U73122 (10 µM). The mean length of 50 muscle cells
was measured by scanning micrometry and was compared with the length of untreated
muscle cells. The contractile response was expressed as the percent decrease in the mean
cell length from control cell length. Melatonin induced a significant decrease in cell
muscle length that was blocked by the PLC-β inhibitor, U73122 (10 µM). Values are
means±SEM of 6-8 experiments.
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D- DISCUSSION

Melatonin release from pineal gland displays a circadian rhythmic pattern with
the increased release during nighttime and decreased release during the daytime.
Melatonin is also released from serotonin-rich enterochromaffin cells in the gut, but the
release does not exhibit a pronounced circadian rhythm but seems to depend on the
nutritional state.

Melatonin regulates rhythmic changes in gastrointestinal motility.

Several in vitro studies in isolated muscle strips demonstrated that the actions of
melatonin are complex and involve both direct and indirect effects on smooth muscle
including antagonistic relationship between serotonin and melatonin [95-100, 115-121].
The present study characterized the signaling pathways mediated by melatonin
receptors in gastric smooth muscle cells using biochemical, molecular and functional
methods. The results demonstrate the expression of MT1, but not MT2 receptors in
gastric smooth muscle cells and their ability to stimulate PLC-β activity, increase
intracellular Ca2+ and induce smooth muscle contraction.
The evidence for the coupling of MT1 receptors to Gq-dependent stimulation of
PLC-β activity and to elicit muscle contraction was based on a combination of
experimental strategies.
(i) mRNA and protein expression of MT1 was demonstrated in cultured muscle
cells by RT-PCR and in isolated muscle cells by western blot. MT2 receptors are not
detected by RT-PCR or western blot analysis, raising the possibility that the expression of
these proteins is either absent or not abundant in these cells.

The selective expression of

MT1 receptors in smooth muscle cells of the gut is consistent with their expression in
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other cells types of the gut. Receptors for melatonin have been identified in the gut of
several species. Storr et al [96, 97] has demonstrated the expression of MT1, but not MT2
receptors using RNA isolated from the muscle layers of stomach and intestine. The
distribution of melatonin receptors through the gut seems to vary with species [122, 123)
and their density as well as their affinity for the ligand may vary over the photoperiod
[124].
(ii) The MT1 receptors are coupled to activation of Gq. Selective activation of Gq
was demonstrated using [35S]GTPγS and subtype-selective G protein antibodies.
[35S]GTPγS.Gα complexes activated by melatonin bound selectively to Gαq antibodies
reflecting activation of Gq proteins. No melatonin induced increase in the binding to
Gαi1, Gαi2, Gαi3, or Gαs antibodies to [35S]GTPγS could be detected. Studies in various
cell lines suggest that MT1 are coupled to both PTx-sensitive and PTx–insensitive G
proteins [83, 115]. Our studies demonstrate that MT1 receptors are coupled to PTXinsensitive Gq protein. The coupling of MT1 to G proteins likely depends on the cell type
and the relative abundance of G protein subtype.
(iii) Melatonin caused an increase in PLC-β activity (PI hydrolysis) in a
concentration-dependent fashion. The extent of increase was similar to that obtained
with other Gq-coupled receptors (e.g., muscarinic m3 receptors) in gastric smooth muscle
cells. Previous studies in these muscle cells have shown that receptors coupled to both
Gq and Gi proteins stimulate PI hydrolysis via distinct PLC-β isoforms. Gq coupled
receptors such as muscarinic m3, sphingosine-1-phosphate 2 (S1P2), endothelin ETA,
purinergic P2Y2, and NPY2 are coupled to stimulation of PI hydrolysis via Gαqdependent PLC-β1 isozyme, whereas Gi3-coupled m2, P2Y2, and adenosine A1
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receptors, Gi1-coupled somatostatin sst3 receptors, Gi2-coupled opioid, µ, κ, δ receptors,
and Gi1/2-coupled S1P2 receptors are coupled to stimulation of PI hydrolysis via Gβγi dependent PLC-β3 isozyme [106-108, 112]. Thus, P2Y2 and S1P2 receptors are coupled
to stimulation of PI hydrolysis via both Gαq-dependent PLC-β1 isozyme and Gβγidependent PLC-β3 isozyme. Although all four PLC-β isozymes are expressed in the
smooth muscle of the gut, neither PLC-β2 nor PLC-β4 is activated [104]. PLC-β1 is
activated via binding of its COOH-terminal tail, a characteristic feature of PLC-β
isozymes, to Gαq, whereas PLC-β3 is activated via binding to its NH2-terminal
pleckstrin homology (PH) domain to Gβγi. Phosphatidylinositol 4,5-bisphosphate (PIP2)
is the predominant phosphoinositide substrate hydrolyzed by both PLC-β1 and PLC-β3
isozyme, resulting in the generation of diacylglycerol, an activator of protein kinase C
(PKC) and inositol 1,4,5-trisphosphate (IP3), a diffusible Ca2+-mobilizing messenger.
The specific G proteins involved in the stimulation of PLC-β activity by
melatonin was examined using minigene approach. Previous studies have shown that the
COOH-terminus of G protein α subunits is critical in mediating receptor-G protein
interaction and peptides corresponding to COOH-terminus serve as competitive inhibitors
of receptor-G protein interaction [112, 113].

The minigene plasmid vectors were

designed to express the COOH-terminal peptide sequences of various Gα subunits after
transfection into cells.

In gastric muscle cells transfection of minigene plasmid

constructs that encode oligonucleotide sequences corresponding to Gαq completely
blocked the activation of PLC-β activity by melatonin. The results provide evidence that
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MT1 receptors are coupled to stimulation of PLC-β activity via Gq and this is consistent
with the selective activation of Gq.
(iv) Melatonin, as other Gq-coupled receptors, induced an increase intracellular
Ca2+ in single muscle cells.

The increase in Ca2+ was not affected by removal

extracellular Ca2+ suggesting that the source of Ca2+ was intracellular. This is consistent
with the activation of PLC-β activity which results in the generation of Ca2+ mobilizing
messenger IP3.
(v) Consistent with the stimulation of PLC-β activity and increase in intracellular
Ca2+ in response to melatonin, addition of melatonin to dispersed gastric muscle cells
elicited rapid (30 s) muscle contraction. Contraction was blocked by the PLC-β inhibitor
U73122. The extent of muscle contraction was similar to the other contractile agonists
such as acetylcholine and substance P [108, 111]. In smooth muscle of the gut, various
Gq protein-coupled receptor agonists initiate contraction by increasing cytosolic Ca2+ via
IP3-dependent Ca2+ release from sarcoplasmic Ca2+ stores. The sarcoplsmic Ca2+ stores
contain high-affinity IP3 receptors and release Ca2+ in response to increase in cytosolic
IP3 levels. Three types IP3 receptors, IP3R-I, IP3 R-II and IP3 R-III, have been cloned.
Although smooth muscle of the gut expresses both IP3 R-I and IP3 R-II, only IP3 R-I is
involved in Ca2+-release in response to receptor activation [110]. The increase Ca2+ and
the binding of Ca2+ to calmodulin results in the stimulation of Ca2+/calmodulin-dependetn
myosin light chain (MLC) kinase activity and phosphorylation of MLC20 at Ser19, a
prerequisite for initiation of actomyosin interaction and muscle contraction [114].
Studies by Lucchelli et al [118] also demonstrated direct contractile effect of
melatonin in gastrointestinal smooth muscle. These studies demonstrated that melatonin
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and its analogues induced contractile responses in guinea pig isolated proximal colon in a
concentration-dependent manner. The rank of agonist potency was: 2-indomelatonin>6chloromelatonin>N-acetyl-5-HT>5-MCA-NAT>melatonin, an order typical for MT2
receptors. However, prazosin, an α-adrenoreceptor antagonist possessing moderate/high
affinity for melatonin MT2 sites had no effect on melatonin-induced contractions. While
the rank order of agonist potencies would suggest the participation of MT2 receptors, the
ineffectiveness of prazosin on melatonin-induced contractions suggests to the contrary.
The lack of MT1 selective anatagonists precluded the conclusion of implicating MT1
receptors. Melatonin responses were also resistant to atropine and tetradotoxin suggesting
a direct effect on muscle cells.
In contrast to contractile effect, studies by Storr et al [96, 97] have demonstrated
that addition of melatonin to isolated gastric and intestine muscle strips caused inhibition
of NANC-mediated muscle relaxation via MT1 receptors. These studies indicate the
difficulties in identifying the signaling pathways activated by melatonin in innervated
muscle strips. The effect of melatonin may vary in different species and different regions
of the gut depending on whether the activated receptor is present predominantly on smooth
muscle cells or enteric neurons. Our studies provide evidence for the involvement of MT1
receptors in melatonin-induced contraction is isolated muscle cell devoid of neural
elements.
In summary, the present study demonstrated that gastric smooth muscle cells
express receptors (MT1) for melatonin preferentially coupled to Gq. These receptors are
coupled to stimulation of PLC-β activity and Ca2+ release from intracellular stores
resulting in muscle contraction (Fig. 12).
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Figure 12. Pathway mediating muscle contraction by melatonin. In gastric smooth
muscle, melatonin interacts with MT1 receptors, which is coupled to stimulation of
phosphoinositide-specific phospholipase C (PLC-β) via Gq.

Stimulation of PLC-β

activity results in the generation of inositol 1,4,5-trisphosphate (IP3) and IP3-dependent
Ca2+ release leading to muscle contraction.
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Figure 12
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